Skip to main content

Table 3 Univariate and multivariate Cox regression analysis of clinical characteristics and laboratory indicators on PFS

From: COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study

Characteristics

Univariate analysis

Multivariate analysis

HR

CI 95%

p value

HR

CI 95%

p value

Age

1.005

0.979–1.031

0.700

   

Gender

1.256

0.616–2.558

0.530

   

Smoking

1.551

0.919–2.620

0.100

   

ECOG

1.806

1.047–3.115

0.033

1.441

0.728–2.850

0.294

Treatment line

1.333

0.800–2.220

0.27

   

Combined therapy

0.696

0.361–1.344

0.28

   

Stage

1.869

0.918–3.804

0.085

   

PD-(L)1

0.493

0.271-0.900

0.021

0.572

0.283–1.157

0.120

Vaccination

0.231

0.092–0.579

0.002

0.263

0.091–0.757

0.013

NLR

1.038

1.015–1.061

0.001

1.032

0.992–1.074

0.119

Albumin

0.888

0.849–0.929

0.000

0.955

0.900–1.013

0.127

D-D

1.043

1.000-1.088

0.051

   

CD3(%)

0.999

0.958–1.022

0.530

   

CD4(%)

0.989

0.959–1.020

0.480

   

CD8(%)

1.008

0.977–1.040

0.630

   

CD4/CD8

1.003

0.710–1.418

0.990

   

CD56(%)

1.021

0.987–1.057

0.230

   

CD19(%)

0.980

0.923–1.039

0.500

   

IgM

0.892

0.333–2.390

0.820

   

IgA

1.207

0.788–1.848

0.390

   

IgG

1.040

0.956–1.130

0.360

   

IgE

1.000

0.998–1.001

0.390

   

Fibrinogen

1.518

1.240–1.857

0.000

1.430

1.096–1.864

0.008

  1. NLR Neutrophil-lymphocyte ratio; IgM Immunoglobulin M; IgG, Immunoglobulin G; IgA Immunoglobulin A; IgE, Immunoglobulin E; PFS Progression-free survival
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us